echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Class 1.1 new drug of HongRi Pharmaceutical Co., Ltd. obtained clinical approval

    Class 1.1 new drug of HongRi Pharmaceutical Co., Ltd. obtained clinical approval

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the website of the State Food and Drug Administration (CFDA) on June 25, the declaration status of kurosamine B mesylate and kurosamine B mesylate for injection are changed to "approved - to be certified" Previously, people familiar with the matter said that the drug was the company's KB project, which was approved for clinical use KB, as a class 1.1 new drug, was jointly developed by HongRi pharmaceutical and the First Affiliated Hospital of the Third Military Medical University of the people's Liberation Army It is worth mentioning that this variety is similar to the indications of Xuebijing injection, the main variety of HongRi pharmaceutical, which is used to treat sepsis Xuebijing injection accounts for about 48% of the income of HongRi pharmaceutical industry More than 18 million people suffer from sepsis and more than one million people die every year It is a worldwide medical problem that there is no ideal therapeutic drug in clinic At the 2013 online performance presentation meeting of HongRi pharmaceutical, the company's executives once said that KB project is one of the heavyweight varieties in the company's "R & D pool" KB project is a new drug for the treatment of sepsis category 1 It cooperates with Xuebijing injection, the company's main product, to deepen the field of sepsis treatment.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.